Gliptin-Induced Bullous Pemphigoid: Canadian Case Series of 10 Patients.

Bullous pemphigoid (BP) is a chronic immune-mediated vesiculobullous disorder. Recently, several reports have described dipeptidyl peptidase-4 inhibitors, also known as gliptins, as causative agents for drug-induced BP. To report and describe clinical and histologic characteristics of 10 cases of gliptin-induced BP. We identified 10 patients with gliptin-induced BP. Nine were secondary to linagliptin, and 1 case was attributed to sitagliptin. All patients showed significant improvement after withdrawal of gliptin medications and proper medical treatment. There has been no evidence of relapse after 4 months of follow-up. This report supports the proposed association between gliptins and BP. Physicians should be aware of this potential adverse effect, as gliptin-induced BP can be reversible once identified and the responsible medication is stopped. Early withdrawal of the offending drug and proper treatment can lead to rapid improvement and reduced morbidity.

Citation

Miriam Armanious, Mohn'd AbuHilal. Gliptin-Induced Bullous Pemphigoid: Canadian Case Series of 10 Patients. Journal of cutaneous medicine and surgery. 2021 Mar-Apr;25(2):163-168

PMID: 33176433

search → result